Crispr Therapeutics shares tumble after significant earnings miss
LONDON - abrdn UK Smaller Companies Growth Trust plc (LSE:ASL) has confirmed its compliance with the Market Abuse Regulation (MAR), stating that it has disclosed all necessary inside information to a Regulated Information Service (RIS). This announcement, made on Monday, allows the company to continue purchasing its own securities or issuing shares during the closed period leading up to the release of its Half-Yearly Report for the six months ended December 31, 2024.
The trust has taken into consideration several factors to ensure compliance. These include the disclosure of the net asset value per share as of December 31, 2024, which was announced on January 7, 2025. The company also believes, based on reasonable inquiries, that there will be no significant differences between the information published then and what will be included in the upcoming Half-Yearly Report.
Further ensuring compliance, the trust calculates and announces its net asset values per share each business day, and confirms there is no other unpublished information that could be deemed price-sensitive in respect of the company's securities. Additionally, the company has no unquoted investments within its portfolio, which simplifies the transparency of its financial position.
The adherence to MAR is significant for the trust as it demonstrates its commitment to maintaining fair and transparent markets, a critical aspect for investors' confidence. This compliance is in line with the company's ongoing practices to ensure all regulatory requirements are met.
The information for this statement is based on a press release from abrdn UK Smaller Companies Growth Trust plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.